# Incyte Corporation (INCY) stock news and updates

As of November 20, 2026. Source: https://www.clearthesis.ai/updates/INCY

## Our view on the Incyte Corporation investment thesis

Full investment thesis: https://www.clearthesis.ai/thesis/INCY

## Latest updates on Incyte Corporation

### Mizuho Securities sets a $148 target for Incyte

*November 20, 2026 · analyst · significance: minor · signal: positive*

Mizuho Securities set its price target for the drugmaker at $148. This is higher than the average target of $137 across all analysts who follow the company. While the firm is optimistic, the stock's performance will likely depend on how well the company can grow its newer dermatology treatments. These new products need to generate enough sales to replace the revenue from its core cancer drug, which will lose its patent protection in 2028.

Sources: [Mizuho Securities](https://www.streetinsider.com/Analyst+Comments/Incyte+%28INCY%29+PT+Raised+to+%24148+at+Mizuho/27379706.html)

### Incyte's oral drug for a chronic skin condition wins European approval

*November 17, 2026 · news · significance: notable · signal: positive*

European regulators approved Povofortay for adults with moderate to severe hidradenitis suppurativa, a painful and long-term inflammatory skin condition. This makes it the first once-daily pill available in Europe for this specific condition, offering an alternative to existing injectable treatments. This approval is a helpful step in the company's plan to move beyond its core cancer drugs. By expanding its dermatology portfolio, the business is building new sources of revenue to help offset the impact when its top-selling cancer drug, Jakafi, loses its patent protection in 2028.

Sources: [Business Wire](https://www.businesswire.com/news/home/20261116905792/en/Povofortay%C2%AE-povorcitinib-Approved-in-Europe-as-the-First-Once-Daily-Oral-Treatment-for-Adults-with-Moderate-to-Severe-Hidradenitis-Suppurativa/)

### Incyte partners with Natera for a colorectal cancer study

*November 11, 2026 · news · significance: notable · signal: positive*

Incyte is starting a mid-stage study for its new immunotherapy, INCA33890, in patients with stage 2 or 3 colorectal cancer. The trial will use Natera's Signatera test, which looks for tiny amounts of cancer DNA in the blood to see if a treatment is working or if the cancer is returning. This partnership is a step in Incyte's plan to grow beyond its core blood cancer business. Colorectal cancer is a much larger market than the rare disorders the company currently treats. Using advanced testing to identify which patients are most likely to benefit could help the drug move through the regulatory process faster, which is vital as Incyte prepares for its main drug to lose patent protection in 2028.

Sources: [Business Wire](https://www.businesswire.com/news/home/20261110610640/en/Natera-Announces-Clinical-Collaboration-with-Incyte-on-Interventional-Phase-II-Study-in-Colorectal-Cancer/)

### Oppenheimer upgraded Incyte to its version of a buy rating

*October 30, 2026 · analyst · significance: major · signal: positive*

Oppenheimer raised its rating on the stock to outperform on Friday. The move comes a day after the company reported that its newer skin treatments are growing quickly, which helps address concerns about older drugs losing their patent protection in a few years. The firm set a price target of $144, which is about 18 percent higher than where the stock is currently trading. Other analysts also nudged their targets higher this week, bringing the average across all firms to $138.

Sources: [Oppenheimer](https://www.streetinsider.com/Analyst+Comments/Oppenheimer+Upgrades+Incyte+%28INCY%29+to+Outperform/27259856.html)

### We updated our thesis on Incyte

*October 30, 2026 · news · significance: notable · signal: watch*

After Incyte reported its October results, we updated our fair value and cut our quality score to 3.1. We moved our rating to Watch and reset our expectations for how much profit the business keeps after spending on research. We have added the impact of one-time government legal settlements to what we track to better monitor underlying drug demand. We also added the cost and volatility of buying external drug technology to our analysis as the company works to replace revenue from its older blood cancer medicines.

## Incyte Corporation earnings

In Q3 2026, reported on October 29, 2026, Incyte Corporation posted earnings of $-3.60 per share against $-3.93 expected, and revenue of $1.6 billion against $1.5 billion expected.

The next earnings report is expected on February 9, 2027. Analysts expect $1.91 per share. Revenue is expected around $1.6 billion.

What to watch: Whether Opzelura sales continue growing above 20 percent, as this skin cream is the primary engine for replacing revenue from older drugs.

## Recent analyst activity on INCY

- November 20, 2026: Mizuho Securities Set target. Price target: $148.00.
- November 17, 2026: Jefferies Set target. Price target: $115.00.
- November 5, 2026: Leerink Partners Kept rating at Outperform.
- November 2, 2026: Bernstein Kept rating at Market Perform.
- October 30, 2026: Oppenheimer Upgraded to Outperform, set target. Price target: $144.00.
- October 30, 2026: Evercore ISI Group Kept rating at In Line.

## What's ahead for Incyte Corporation

- February 9, 2027: Earnings report — The company shows how it did over the last three months. The most important update for the stock.

---

Published by Clearthesis (https://www.clearthesis.ai). Informational only, not investment advice.
Full page: https://www.clearthesis.ai/updates/INCY
